| 2024 |
| 07/26 | 221 | 233 | 221 | 231 | +3.13% | 238,800 | 93億1030万 | -3.75% |
| 07/25 | 225 | 227 | 222 | 224 | -0.88% | 273,100 | 90億2817万 | -6.28% |
| 07/24 | 229 | 233 | 225 | 226 | -1.31% | 721,200 | 91億878万 | -5.44% |
| 07/23 | 231 | 236 | 228 | 229 | -0.43% | 308,500 | 92億2970万 | -4.18% |
| 07/22 | 241 | 241 | 229 | 230 | -6.12% | 706,500 | 92億7000万 | -3.36% |
| 07/19 | 255 | 255 | 244 | 245 | -3.16% | 658,300 | 98億7456万 | +2.94% |
| 07/18 | 15:00 ストック・オプションとしての新株予約権の発行に関するお知らせ |
| 07/18 | 254 | 261 | 251 | 253 | +0.4% | 996,700 | 101億9700万 | +6.75% |
| 07/17 | 246 | 260 | 244 | 252 | +2.44% | 997,500 | 101億5670万 | +7.23% |
| 07/16 | 243 | 254 | 243 | 246 | +1.23% | 510,400 | 99億1487万 | +5.13% |
| 07/12 | 15:00 2025年2月期第1四半期決算短信〔日本基準〕(非連結) |
| 07/12 | 249 | 251 | 242 | 243 | -4.33% | 792,300 | 97億9396万 | +4.29% |
| 07/11 | 239 | 260 | 239 | 254 | +6.72% | 1,779,200 | 102億3730万 | +9.96% |
| 07/10 | 237 | 239 | 230 | 238 | 0% | 411,000 | 95億9243万 | +3.93% |
| 07/09 | 234 | 241 | 232 | 238 | +2.15% | 520,100 | 95億9243万 | +4.39% |
| 07/08 | 228 | 238 | 226 | 233 | +3.1% | 1,172,300 | 93億9091万 | +2.19% |
| 07/05 | 240 | 242 | 224 | 226 | -7.38% | 2,071,400 | 91億878万 | -0.44% |
| 07/04 | 284 | 293 | 244 | 244 | +2.95% | 9,284,600 | 98億3426万 | +7.96% |
| 07/03 | 15:00 脊髄損傷に対する新規治療薬候補の導入における北海道大学との独占的実施許諾契約締結に関するお知らせ |
| 07/03 | 246 | 248 | 234 | 237 | -3.27% | 491,100 | 95億5213万 | +5.33% |
| 07/02 | 250 | 257 | 245 | 245 | -1.61% | 316,300 | 98億7456万 | +8.89% |
| 07/01 | 257 | 258 | 248 | 249 | -1.58% | 433,800 | 100億3578万 | +11.16% |
| 06/28 | 257 | 261 | 244 | 253 | -0.39% | 649,300 | 101億9700万 | +13.45% |
| 06/27 | 239 | 257 | 237 | 254 | +6.28% | 715,800 | 102億3730万 | +14.41% |
| 06/26 | 235 | 240 | 231 | 239 | +1.7% | 224,800 | 96億3274万 | +8.14% |
| 06/25 | 240 | 250 | 235 | 235 | -0.84% | 712,000 | 94億7152万 | +6.33% |
| 06/24 | 234 | 238 | 229 | 237 | +1.28% | 407,900 | 95億5213万 | +7.24% |
| 06/21 | 220 | 236 | 220 | 234 | +4.93% | 540,700 | 94億3122万 | +5.41% |
| 06/20 | 219 | 231 | 215 | 223 | +4.69% | 830,900 | 89億8787万 | +0.45% |
| 06/19 | 15:00 TMS-008の第I相臨床試験における最初の被験者への投与のお知らせ |
| 06/19 | 219 | 222 | 210 | 213 | -3.18% | 304,400 | 85億8483万 | -4.05% |
| 06/18 | 213 | 226 | 209 | 220 | +3.77% | 452,500 | 88億6696万 | -1.79% |
| 06/17 | 216 | 216 | 208 | 212 | -3.2% | 303,400 | 85億4452万 | -5.36% |
| 06/14 | 216 | 222 | 211 | 219 | -0.9% | 237,900 | 88億2665万 | -3.1% |
| 06/13 | 218 | 228 | 218 | 221 | +1.84% | 205,900 | 89億726万 | -2.64% |
| 06/12 | 15:00 個人投資家向けIRセミナー登壇のお知らせ |
| 06/12 | 229 | 230 | 217 | 217 | -2.25% | 495,600 | 87億4604万 | -4.82% |
| 06/11 | 213 | 224 | 208 | 222 | +5.21% | 719,600 | 89億4756万 | -3.48% |
| 06/10 | 204 | 212 | 204 | 211 | +3.94% | 289,100 | 85億422万 | -8.66% |
| 06/07 | 208 | 209 | 200 | 203 | -2.4% | 302,800 | 81億8178万 | -12.88% |
| 06/06 | 214 | 219 | 208 | 208 | -3.26% | 292,300 | 83億8330万 | -11.49% |
| 06/05 | 220 | 221 | 215 | 215 | -1.83% | 244,400 | 86億6543万 | -8.9% |
| 06/04 | 208 | 222 | 207 | 219 | +4.29% | 284,200 | 88億2665万 | -7.59% |
| 06/03 | 214 | 215 | 206 | 210 | 0% | 339,500 | 84億6391万 | -11.76% |
| 05/31 | 226 | 231 | 196 | 210 | -7.89% | 1,539,100 | 84億6391万 | -12.13% |
| 05/30 | 217 | 235 | 216 | 228 | +3.64% | 242,900 | 91億8939万 | -5% |
| 05/29 | 15:00 事業計画及び成長可能性に関する事項 |
| 05/29 | 233 | 233 | 220 | 220 | -4.76% | 134,900 | 88億6696万 | -8.71% |
| 05/28 | 232 | 236 | 228 | 231 | 0% | 96,900 | 93億1030万 | -4.15% |
| 05/27 | 231 | 232 | 223 | 231 | +1.32% | 157,300 | 93億1030万 | -4.55% |
| 05/24 | 227 | 228 | 221 | 228 | -0.87% | 212,900 | 91億8939万 | -6.17% |
| 05/23 | 235 | 235 | 228 | 230 | -1.71% | 103,300 | 92億7000万 | -5.74% |
| 05/22 | 240 | 240 | 233 | 234 | -2.09% | 106,300 | 94億3122万 | -4.49% |
| 05/21 | 239 | 240 | 237 | 239 | -0.42% | 85,700 | 96億3274万 | -2.85% |
| 05/20 | 240 | 246 | 239 | 240 | +0.42% | 77,400 | 96億7304万 | -2.44% |
| 05/17 | 239 | 243 | 237 | 239 | -0.42% | 131,200 | 96億3274万 | -3.24% |
| 05/16 | 242 | 242 | 236 | 240 | -0.83% | 126,100 | 96億7304万 | -3.23% |
| 05/15 | 246 | 246 | 238 | 242 | -0.41% | 114,000 | 97億5365万 | -2.42% |
| 05/14 | 238 | 255 | 235 | 243 | +1.67% | 227,900 | 97億9396万 | -2.41% |
| 05/13 | 245 | 245 | 239 | 239 | -2.45% | 130,100 | 96億3274万 | -4.4% |
| 05/10 | 253 | 254 | 245 | 245 | -2.78% | 170,500 | 98億7456万 | -2.39% |
| 05/09 | 256 | 259 | 248 | 252 | -2.7% | 199,100 | 101億5670万 | 0% |
| 05/08 | 256 | 261 | 254 | 259 | +1.97% | 379,300 | 104億3883万 | +2.78% |
| 05/08 | 9:00 SMTP化合物関連特許(日本)に関するお知らせ |
| 05/07 | 259 | 260 | 251 | 254 | -0.78% | 197,300 | 102億3730万 | +0.4% |
| 05/02 | 258 | 265 | 252 | 256 | -1.16% | 260,100 | 103億1791万 | +0.79% |
| 05/01 | 246 | 262 | 243 | 259 | +5.28% | 256,300 | 104億3883万 | +1.57% |
| 04/30 | 240 | 246 | 236 | 246 | +4.24% | 110,800 | 99億1487万 | -3.91% |
| 04/26 | 238 | 241 | 232 | 236 | -0.42% | 133,900 | 95億1183万 | -8.53% |
| 04/25 | 242 | 245 | 237 | 237 | -3.66% | 194,400 | 95億5213万 | -9.2% |
| 04/24 | 236 | 246 | 236 | 246 | +4.24% | 172,800 | 99億1487万 | -6.46% |
| 04/23 | 240 | 248 | 234 | 236 | +1.72% | 440,800 | 95億1183万 | -10.94% |
| 04/22 | 233 | 234 | 229 | 232 | -0.43% | 280,000 | 93億5061万 | -13.11% |
| 04/19 | 249 | 250 | 223 | 233 | -7.91% | 780,900 | 93億9091万 | -13.38% |
| 04/18 | 250 | 258 | 247 | 253 | +1.61% | 237,200 | 101億9700万 | -6.64% |
| 04/17 | 15:00 2024年2月期決算説明資料 |
| 04/17 | 257 | 260 | 249 | 249 | -4.23% | 236,700 | 100億3578万 | -8.79% |
| 04/16 | 260 | 261 | 256 | 260 | +1.56% | 204,200 | 104億7913万 | -5.45% |
| 04/15 | 243 | 262 | 243 | 256 | +3.23% | 500,600 | 103億1791万 | -7.25% |
| 04/12 | 15:00 2024年2月期決算短信〔日本基準〕(非連結) |
| 04/12 | 15:00 個別業績の前年実績との差異に関するお知らせ |
| 04/12 | 259 | 259 | 248 | 248 | -2.75% | 296,000 | 99億9548万 | -10.79% |
| 04/11 | 255 | 255 | 247 | 255 | +0.39% | 299,200 | 102億7761万 | -8.93% |
| 04/10 | 258 | 262 | 251 | 254 | -1.55% | 286,600 | 102億3730万 | -10.25% |
| 04/09 | 260 | 266 | 258 | 258 | -0.39% | 206,300 | 103億9852万 | -9.47% |
| 04/08 | 269 | 269 | 259 | 259 | -3% | 155,300 | 104億3883万 | -10.07% |
| 04/05 | 263 | 267 | 257 | 267 | +0.38% | 171,700 | 107億6126万 | -7.93% |
| 04/04 | 263 | 269 | 256 | 266 | +4.31% | 280,000 | 107億2096万 | -8.9% |
| 04/03 | 259 | 263 | 254 | 255 | -3.77% | 352,900 | 102億7761万 | -13.56% |
| 04/02 | 273 | 273 | 260 | 265 | -2.57% | 473,800 | 106億8065万 | -11.07% |
| 04/01 | 278 | 280 | 271 | 272 | -3.2% | 311,600 | 109億6278万 | -9.33% |
| 03/29 | 277 | 282 | 276 | 281 | +1.44% | 157,700 | 113億2552万 | -6.64% |
| 03/28 | 287 | 287 | 275 | 277 | -2.46% | 260,500 | 111億6430万 | -7.97% |
| 03/27 | 284 | 287 | 270 | 284 | -0.35% | 425,200 | 114億4644万 | -5.96% |
| 03/26 | 293 | 296 | 285 | 285 | -2.4% | 358,200 | 114億8674万 | -5.63% |
| 03/25 | 291 | 298 | 290 | 292 | -1.02% | 262,100 | 117億6887万 | -2.99% |
| 03/22 | 299 | 300 | 291 | 295 | -1.67% | 406,300 | 118億8978万 | -1.67% |
| 03/21 | 296 | 304 | 294 | 300 | +1.35% | 365,600 | 120億9131万 | 0% |
| 03/19 | 294 | 296 | 288 | 296 | +0.68% | 300,800 | 119億3009万 | -1% |
| 03/18 | 283 | 298 | 283 | 294 | +6.14% | 547,000 | 118億4948万 | -1.67% |
| 03/15 | 280 | 285 | 275 | 277 | -2.46% | 315,600 | 111億6430万 | -7.67% |
| 03/14 | 286 | 294 | 274 | 284 | -1.73% | 633,500 | 114億4644万 | -5.65% |
| 03/13 | 299 | 300 | 287 | 289 | -3.67% | 470,500 | 116億4796万 | -3.67% |
| 03/12 | 292 | 301 | 288 | 300 | +1.01% | 405,100 | 120億9131万 | +0.33% |
| 03/11 | 292 | 301 | 290 | 297 | -1% | 580,100 | 119億7039万 | -0.34% |
| 03/08 | 293 | 309 | 286 | 300 | 0% | 1,040,700 | 120億9131万 | +0.67% |
| 03/07 | 322 | 325 | 299 | 300 | -7.12% | 1,333,600 | 120億9131万 | +1.01% |
| 03/06 | 316 | 323 | 312 | 323 | +1.89% | 659,900 | 130億1831万 | +8.75% |
| 03/05 | 312 | 322 | 305 | 317 | -0.63% | 1,119,400 | 127億7648万 | +7.82% |
| 03/04 | 315 | 328 | 310 | 319 | +1.59% | 1,178,600 | 128億5709万 | +8.87% |
| 02/29 | 16:45 TMS-008の国内第1相臨床試験における治験計画届出書提出のお知らせ |
